Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Severe Acute Respiratory Syndrome 1Mastocytosis 1Hypersensitivity 1COVID-19 1

Interventions

fludarabine 63Cyclophosphamide 63venetoclax 58Azacitidine 54fludarabine phosphate 50Specimen Handling 44ruxolitinib 40Whole-Body Irradiation 40Mycophenolic Acid 37Tacrolimus 35Melphalan 32Busulfan 32Biopsy 32Cytarabine 31Decitabine 28Stem Cell Transplantation 27Granulocyte Colony-Stimulating Factor 21Injections 20asciminib 19decitabine and cedazuridine drug combination 18Sirolimus 18Peripheral Blood Stem Cell Transplantation 18Thiotepa 17Filgrastim 17nilotinib 15X-Rays 14Methotrexate 14Cyclosporine 14Imatinib Mesylate 13Magnetic Resonance Spectroscopy 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
BNT162 Vaccine × Myeloid × 1 year × Clear all
NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
746 enrolled 28 charts
Myeloid

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡